Azienda Sanitaria Locale Viterbo
- Address
- lock Available on a paid plan
Azienda Sanitaria Locale Viterbo - Oncology & Hematology Research Center
Azienda Sanitaria Locale Viterbo is a comprehensive clinical research center with particular expertise in oncology and hematology. The center demonstrates significant involvement in advanced cancer therapeutics, focusing on precision medicine approaches and novel treatment combinations across multiple tumor types. Their research portfolio emphasizes the integration of targeted therapies, immunotherapies, and innovative biomarker-driven treatment strategies.
- Breast cancer treatment optimization, including hormone receptor-positive disease and BRCA-mutated tumors with adjuvant and metastatic settings
- Gastrointestinal malignancies, particularly colorectal cancer with focus on liquid biopsy, RAS/BRAF mutations, and personalized sequencing strategies
- Genitourinary cancers including metastatic renal cell carcinoma and castration-resistant prostate cancer with novel therapeutic combinations
- Hematologic malignancies including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms
The center's research extends beyond oncology to include chronic kidney disease and cardiovascular complications in dialysis patients, demonstrating a multidisciplinary approach. Their participation in phase II and III trials reflects a commitment to translating cutting-edge scientific discoveries into clinical practice, with particular emphasis on circulating tumor DNA analysis, immunotherapy combinations, and personalized treatment intensification based on molecular profiling and biomarker assessment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 50 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Locale Viterbo
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 50 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 2 | Unknown | 2024-10-28 | 2024-12-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.